<?xml version="1.0" encoding="UTF-8"?>
<wcm:root xmlns:wcm="http://www.stellent.com/wcm-data/ns/8.0.0">
  <wcm:element name="MainContent">&lt;table id="schedule" border="0" cellspacing="0" summary="This table shows the date, time, and location of the meeting" cellpadding="2" style="width: 100%"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;th id="a1" bgcolor="#cccccc" valign="top" width="10%" align="left"&gt;Center&lt;/th&gt;&lt;th id="a2" bgcolor="#cccccc" valign="top" width="25%" align="left"&gt;Date&lt;/th&gt;&lt;th id="a3" bgcolor="#cccccc" valign="top" width="25%" align="left"&gt;Time&lt;/th&gt;&lt;th id="a4" bgcolor="#cccccc" valign="top" width="40%" align="left"&gt;Location&lt;/th&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="10%" headers="a1"&gt;OC&lt;/td&gt;&lt;td valign="top" width="25%" headers="a2"&gt;April 21, 2014&lt;/td&gt;&lt;td valign="top" width="25%" headers="a3"&gt;8:00 a.m. - 5:00 p.m.&lt;/td&gt;&lt;td valign="top" width="40%" headers="a4"&gt;Bethesda Marriott&lt;br /&gt;5151 Pooks Hill Road&lt;br /&gt;Bethesda, MD 20814&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;h4&gt;Agenda&lt;/h4&gt;&lt;p&gt;On April 21, 2014, the Pediatric Advisory Committee (PAC) will meet to discuss pediatric-focused safety reviews, as mandated by the Best Pharmaceuticals for Children Act (Pub. L. 107&amp;ndash;109) and the Pediatric Research Equity Act (Pub. L. 108&amp;ndash;155). The PAC will meet to discuss Activa Dystonia Therapy, ADVATE (antihemophilic factor (recombinant)), FAMVIR (famciclovir), INTELENCE (etravirine), KEPPRA (levetiracetam), MAXALT and MAXALT MLT&amp;nbsp; (rizatriptan), NATAZIA (estradiol valerate and estradiol valerate/dienogest), PERTZYE (pancrelipase), PERZISTA (darunavir), REYATAZ (atazanavir), SKLICE (ivermectin), TISSEEL (fibrin sealant), TORISEL (temsirolimus), ULTRESA (pancrelipase), Vertical Expandable Prosthetic Titanium Rib (VEPTR), and VIREAD (tenofovir disoproxil fumarate).&lt;/p&gt;&lt;h4&gt;&lt;strong&gt;Meeting Materials&lt;/strong&gt;&lt;/h4&gt;&lt;p&gt;FDA intends to make the complete set of background material available to the public no later than 2 business days before the meeting. If FDA is unable to post the background material on its Web site prior to the meeting, the background material will be made publicly available at the location of the advisory committee meeting, and the background material will be posted on FDA&amp;rsquo;s website after the meeting.&lt;/p&gt;&lt;ul&gt;&lt;li&gt;&lt;strong&gt;Background material&lt;/strong&gt; &lt;ul&gt;&lt;li&gt;&lt;a target="" href="[!--$wcmUrl('link','UCM385049')--]"&gt;2014 Meeting Materials, Pediatric Advisory Committee&lt;/a&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;/ul&gt;&lt;h4&gt;&lt;strong&gt;Public Participation and Sponsor Information&lt;/strong&gt;&amp;nbsp;&lt;/h4&gt;&lt;p&gt;Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person on or before April 14, 2014. Oral presentations from the public will be scheduled on April 21, 2014, between approximately 11:30 a.m. and 12:30 p.m. Those individuals interested in making formal oral presentations should notify the contact person and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation on or before April 4, 2014. Time allotted for each presentation may be limited. If the number of registrants requesting to speak is greater than can be reasonably accommodated during the scheduled open public hearing session, FDA may conduct a lottery to determine the speakers for the scheduled open public hearing session. The contact person will notify interested persons regarding theirrequest to speak by April 7, 2014.&lt;/p&gt;&lt;p&gt;Persons attending FDA's advisory committee meetings are advised that the Agency is not responsible for providing access to electrical outlets.&lt;/p&gt;&lt;p&gt;FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with physical disabilities or special needs. &amp;nbsp;If you require special accommodations due to a disability, please contact Walter Ellenberg at 301-796-0885, at least 7 days in advance of the meeting.&lt;/p&gt;&lt;p&gt;FDA is committed to the orderly conduct of its advisory committee meetings. &amp;nbsp;Please visit our Web site for &lt;a target="" href="[!--$wcmUrl('link','ucm111462.htm')--]"&gt;procedures on public conduct during advisory committee meetings&lt;/a&gt;.&lt;/p&gt;&lt;h4&gt;&lt;strong&gt;Contact Information&lt;/strong&gt;&lt;/h4&gt;&lt;p&gt;Walter Ellenberg, Ph.D.&lt;br /&gt;Office of Pediatric Therapeutics&lt;br /&gt;Office of the Commissioner&lt;br /&gt;Food and Drug Administration&lt;br /&gt;Bldg. 32, Room 5154&lt;br /&gt;10903 New Hampshire Ave..&lt;br /&gt;Silver Spring, Maryland 20993&lt;/p&gt;&lt;p&gt;Phone: 301&amp;ndash;796-0885&lt;br /&gt;Fax: 301-847-8640&lt;br /&gt;E-mail: &lt;a href="mailto:walter.ellenberg@fda.hhs.gov"&gt;walter.ellenberg@fda.hhs.gov &lt;/a&gt;&lt;/p&gt;&lt;ul&gt;&lt;li&gt;FDA Advisory Committee Information Line&lt;br /&gt;1-800-741-8138&lt;br /&gt;(301-443-0572 in the Washington DC area)&lt;br /&gt;Please call the Information Line for up-to-date information on this meeting.&lt;/li&gt;&lt;/ul&gt;&lt;p&gt;A notice in the &lt;em&gt;Federal Register&lt;/em&gt; about last-minute modifications that impact a previously announced advisory committee meeting cannot always be published quickly enough to provide timely notice. Therefore, you should always check the Agency&amp;rsquo;s Web site at &lt;a target="" href="[!--$wcmUrl('nodelink','1840')--]"&gt;www.fda.gov/AdvisoryCommittees/default.htm&lt;/a&gt; and scroll down to the appropriate advisory committee meeting link, or call the advisory committee information line to learn about possible modifications before coming to the meeting.&lt;/p&gt;&lt;p&gt;Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app.2).&lt;/p&gt;</wcm:element>
<wcm:element name="MainList1"></wcm:element>
  <wcm:element name="MainList2"></wcm:element>
  <wcm:element name="MainList3"></wcm:element>
</wcm:root>
